Ligand Pharmaceuticals Inc (LGND)
114.25
+0.87
(+0.77%)
USD |
NASDAQ |
Dec 26, 16:00
114.79
+0.54
(+0.47%)
Pre-Market: 08:32
Ligand Pharmaceuticals Research and Development Expense (Quarterly): 5.675M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cellectar Biosciences Inc | 5.494M |
| Revance Therapeutics Inc | 11.38M |
| Pieris Pharmaceuticals Inc | -0.446M |
| Zymeworks Inc | 36.35M |
| CNS Pharmaceuticals Inc | 4.245M |